Iran gave green light to the emergency use of Spikogen, a coronavirus vaccine jointly developed by Iranian and Australian pharmaceutical companies.
The announcement was made by Haleh Hamedifar, CEO of the Iranian pharmaceutical CinnaGen Company, which has produced Spikogen in collaboration with Australia.
The results of clinical studies on Spikogen indicated that the vaccine has produced a robust immune response in 87% of recipients, Tasnim News Agency reported.
The vaccine has been proved to be safe with an acceptable degree of tolerability, according to the results of the second phase of clinical trials, Hamedifar added.
The first phase of the tests on Spikogen had been carried out in Australia and the second and third phases began simultaneously in Iran.
In August, Hamedifar said that CinnaGen Company will start the vaccine’s mass production.
Iranian scientists and experts have succeeded in developing several vaccines against the coronavirus, despite the cruel sanctions imposed by the US.
Human injection of the first phase of clinical studies of the first coronavirus vaccine, COVIran Bareket, made by Iranian researchers, began on December 29, 2020.
Iran has already granted emergency use authorization to Russian-made Sputnik V vaccine, Covaxin made by India’s Bharat Biotech, Oxford/AstraZeneca developed by Russia’s R-Pharm Group, AstraZeneca-SKBio made in South Korea and PastuCovac vaccine, produced jointly by Iran’s Pasteur Institute and Cuba’s Finlay Vaccine Institute.
Earlier on Wednesday, Iran's Health Ministry announced the country has registered the lowest daily number of deaths caused by COVID-19 since the fifth peak of the coronavirus spread nationwide.
According to a statement by the ministry, the daily COVID-19 deaths and infections reached 216 and 10,497 respectively, from Tuesday to Wednesday.
It added the total COVID-19 death toll and infections since the beginning of the outbreak in the country in late February 2020 stand at 121,779 and 5,662,458, respectively.
According to the ministry, 5,598 COVID-19 patients are in critical condition, and of the newly-detected cases, 1,805 patients have been hospitalized.
It added that 5,153,048 COVID-19 patients have so far either recovered from the disease or have been discharged from hospitals.
According to the statement, 32,829,944 coronavirus diagnostic tests have so far been carried out in the country.
It added that 60,417,945 doses of COVID-19 vaccines have so far been administrated across Iran.
The ministry said 16 cities in the country are coded red (very high-risk), while 198 are in the orange zone (high-risk).
The number of the country’s yellow (medium-risk) and blue (low-risk) cities are 176 and 58, respectively, according to the ministry.
Iran has been grappling with a fifth wave of the COVID-19 pandemic since a few weeks ago, mainly sparked by the spread of the Indian coronavirus variant, known as Delta, seeing a resurgence in deaths and infections. The number of casualties, however, has been declining since a few days ago, indicating that the country is past the peak of the fifth wave’s infections and deaths.